4.5 Article

Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure-Degradation Relationships

Journal

CHEMMEDCHEM
Volume 13, Issue 15, Pages 1508-1512

Publisher

WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.201800271

Keywords

cereblon; condensation reactions; imides; immunomodulatory drugs; protein degradation

Funding

  1. Alexander von Humboldt Foundation
  2. US National Institutes of Health [R35CA197589]

Ask authors/readers for more resources

The immunomodulatory drugs (IMiDs) thalidomide, pomalidomide, and lenalidomide have been approved for the treatment of multiple myeloma for many years. Recently, their use as E3 ligase recruiting elements for small-molecule-induced protein degradation has led to a resurgence in interest in IMiD synthesis and functionalization. Traditional IMiD synthesis follows a stepwise route with multiple purification steps. Herein we describe a novel one-pot synthesis without purification that provides rapid access to a multitude of IMiD analogues. Binding studies with the IMiD target protein cereblon (CRBN) reveals a narrow structure-activity relationship with only a few compounds showing sub-micromolar binding affinity in the range of pomalidomide and lenalidomide. However, anti-proliferative activity as well as Aiolos degradation could be identified for two IMiD analogues. This study provides useful insight into the structure-degradation relationships for molecules of this type as well as a rapid and robust method for IMiD synthesis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Biochemistry & Molecular Biology

Recent Developments in PROTAC-Mediated Protein Degradation: From Bench to Clinic

Zhenyi Hu, Craig M. Crews

Summary: PROTACs are an emerging technology that utilizes the ubiquitin-proteasome system for targeted protein degradation, showing great therapeutic potential in treating diseases. Over the past two decades, significant advancements have been made in PROTAC technology, with an increasing repertoire of targets.

CHEMBIOCHEM (2022)

Review Biotechnology & Applied Microbiology

PROTAC targeted protein degraders: the past is prologue

Miklos Bekes, David R. Langley, Craig M. Crews

Summary: Targeted protein degradation (TPD) is a new therapeutic modality that can tackle disease-causing proteins which are difficult to target with conventional small molecules. PROTAC molecules, utilizing the ubiquitin-proteasome system to degrade target proteins, has achieved clinical proof-of-concept and attracted significant industry activity. Future directions include identifying target classes suitable for TPD, expanding the use of ubiquitin ligases for precision medicine, and extending the modality beyond oncology.

NATURE REVIEWS DRUG DISCOVERY (2022)

Article Chemistry, Multidisciplinary

Hijacking Methyl Reader Proteins for Nuclear-Specific Protein Degradation

Dhanusha A. Nalawansha, Ke Li, John Hines, Craig M. Crews

Summary: This study introduces a novel approach to induce protein degradation by hijacking a methyl reader:E3 ligase complex, demonstrating nuclear-specific degradation of FKBP12 and BRD2.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2022)

Article Biochemistry & Molecular Biology

Targeted Degradation of mRNA Decapping Enzyme DcpS by a VHL-Recruiting PROTAC

Jake C. Swartzel, Michael J. Bond, Andreas P. Pintado-Urbanc, Mehana Daftary, Mackenzie W. Krone, Todd Douglas, Evan J. Carder, Joshua T. Zimmer, Takahiro Maeda, Matthew D. Simon, Craig M. Crews

Summary: The RNA decapping scavenger protein DcpS has been identified as a dependency in acute myeloid leukemia (AML), and its inhibition or knockdown shows antiproliferative effects on AML cells. The non-essential nature of DcpS in normal human hematopoietic cells suggests potential for therapeutic intervention in AML by modulating DcpS activity. JCS-1, a PROTAC developed in this study, effectively degrades DcpS in nanomolar concentrations, offering a new strategy for AML and other DcpS-dependent genetic disorders.

ACS CHEMICAL BIOLOGY (2022)

Article Biochemistry & Molecular Biology

TAPBPR employs a ligand-independent docking mechanism to chaperone MR1 molecules

Andrew C. McShan, Christine A. Devlin, Georgia F. Papadaki, Yi Sun, Adam I. Green, Giora I. Morozov, George M. Burslem, Erik Procko, Nikolaos G. Sgourakis

Summary: This study reveals the binding mechanism of tapasin and TAPBPR with MR1 protein, promoting its trafficking and cell surface expression. Unlike MHC-I, TAPBPR can recognize MR1 in a ligand-independent manner and induce similar adaptations to those seen in MHC-I/TAPBPR co-crystal structures. Additionally, TAPBPR can affect the exchange kinetics of noncovalent metabolites with the MR1 groove, serving as a catalyst.

NATURE CHEMICAL BIOLOGY (2022)

Article Chemistry, Multidisciplinary

Targeted Dephosphorylation of Tau by Phosphorylation Targeting Chimeras (PhosTACs) as a Therapeutic Modality

Zhenyi Hu, Po-Han Chen, Wenxue Li, Todd Douglas, John Hines, Yansheng Liu, Craig M. Crews

Summary: Microtubule-associated protein tau is crucial for microtubule assembly and stabilization. Tau hyperphosphorylation is implicated in the development of Alzheimer's disease and tauopathies. In this study, we used small molecule-based PhosTACs to induce efficient and sustained tau dephosphorylation by recruiting tau to PP2A, a native tau phosphatase. Mass spectrometry data validated that PhosTACs downregulated multiple phosphorylation sites of tau. Our findings suggest that PhosTACs represent a potential avenue for disease-modifying therapies for tauopathies.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2023)

Review Oncology

Protein degraders enter the clinic - a new approach to cancer therapy

Deborah Chirnomas, Keith R. Hornberger, Craig M. Crews

Summary: Protein degraders are a novel therapeutic modality that selectively target disease-associated proteins for elimination. They have advantages over traditional small-molecule inhibitors and have shown promising activity as cancer therapies in clinical trials. More evidence is needed, but protein degraders represent a new class of drugs for cancer treatment.

NATURE REVIEWS CLINICAL ONCOLOGY (2023)

Article Multidisciplinary Sciences

Chemical interactions that govern the structures of metals

Yuanhui Sun, Lei Zhao, Chris J. Pickard, Russell J. Hemley, Yonghao Zheng, Maosheng Miao

Summary: Most metals have simple structures, but undergo complex transitions on compression. First-principles calculations can reproduce observed structures and transitions, but a unified predictive theory is lacking. By analyzing electronic properties, a simple theory shows that the stability of metal structures is governed by electrons in interstitial orbitals and their chemical interactions. This theory provides a basis for understanding and predicting structures in solid compounds and alloys.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2023)

Article Multidisciplinary Sciences

Universal open MHC-I molecules for rapid peptide loading and enhanced complex stability across HLA allotypes

Yi Sun, Michael C. Young, Claire H. Woodward, Julia N. Danon, Hau Truong, Sagar Gupta, Trenton J. Winters, Joan Font-Burgada, George M. Burslem, Nikolaos G. Sgourakis

Summary: This study created stable MHC-I molecules capable of accepting low-to moderate-affinity peptides through an engineered disulfide bond bridging conserved epitopes. The effects of the disulfide bond on the conformation of the MHC-I structure were characterized using solution NMR. The structure-guided design provides a universal platform for screening antigenic epitope libraries and studying polyclonal TCR repertoires covering highly polymorphic HLA-I allotypes and oligomorphic nonclassical molecules.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2023)

Article Multidisciplinary Sciences

Xeno interactions between MHC-I proteins and molecular chaperones enable ligand exchange on a broad repertoire of HLA allotypes

Yi Sun, Georgia F. Papadaki, Christine A. Devlin, Julia N. Danon, Michael C. Young, Trenton J. Winters, George M. Burslem, Erik Procko, Nikolaos G. Sgourakis

Summary: Immunological chaperones tapasin and TAP binding protein, related (TAPBPR) play key roles in antigenic peptide optimization and quality control of nascent class I major histocompatibility complex (MHC-I) molecules. The polymorphic nature of MHC-I proteins leads to a range of allelic dependencies on chaperones for assembly and cell-surface expression, limiting chaperone-mediated peptide exchange to a restricted set of human leuko-cyte antigen (HLA) allotypes. By studying a chicken TAPBPR ortholog and its interactions with a repertoire of HLA allotypes, this study discovers that TAPBPR orthologs have broader allele specificity in recognizing empty MHC-I and facilitate peptide exchange by maintaining a reservoir of receptive molecules. Mutations in human TAPBPR resembling the chicken sequence are found to enhance HLA-A*01:01 expression and promote peptide exchange. These findings suggest the possibility of engineering polymorphic sites on MHC-I and chaperone surfaces to manipulate their interactions and enable chaperone-mediated peptide exchange on disease-relevant HLA alleles.

SCIENCE ADVANCES (2023)

Article Medicine, Research & Experimental

RAB27B controls palmitoylation-dependent NRAS trafficking and signaling in myeloid leukemia

Jian-Gan Ren, Bowen Xing, Kaoshen Lv, Rachel A. O'Keefe, Mengfang Wu, Ruoxing Wang, Kaylyn M. Bauer, Arevik Ghazaryan, George M. Burslem, Jing Zhang, Ryan M. O'Connell, Vinodh Pillai, Elizabeth O. Hexner, Mark R. Philips, Wei Tong

Summary: RAB27B controls the palmitoylation and trafficking of NRAS, and its expression is associated with poor prognosis in AMLs. RAB27B depletion inhibits the growth of CBL-deficient or NRAS-mutant cell lines.

JOURNAL OF CLINICAL INVESTIGATION (2023)

Article Chemistry, Multidisciplinary

Lead-oriented synthesis of epigenetic relevant scaffolds

Timothe Maujean, Prakash Kannaboina, Adam I. Green, George M. Burslem

Summary: We developed a simple and rational method to rank lead-likeness of molecules using continuous evaluation functions, which has proven to be competitive against known methods and has helped in selecting promising candidate molecules for epigenetic applications.

CHEMICAL COMMUNICATIONS (2023)

Article Biochemistry & Molecular Biology

OligoTRAFTACs: A generalizable method for transcription factor degradation

Kusal T. G. Samarasinghe, Elvira An, Miriam A. Genuth, Ling Chu, Scott A. Holley, Craig M. Crews

Summary: The second generation transcription factor targeting chimeras (oligoTRAFTACs) were developed to induce the degradation of oncogenic transcription factors, c-Myc and brachyury, and their activity was demonstrated in chordoma cell lines and zebrafish experiments.

RSC CHEMICAL BIOLOGY (2022)

Review Chemistry, Multidisciplinary

PROTACs: past, present and future

Ke Li, Craig M. Crews

Summary: PROTACs are a type of molecules with novel event-driven mechanism, offering multiple advantages over traditional inhibitors, such as catalytic nature and targeted protein degradation, which may lead to improved therapeutic outcomes with reduced toxicity. However, further research and development efforts are needed to fully explore their potential.

CHEMICAL SOCIETY REVIEWS (2022)

Review Biochemistry & Molecular Biology

Targeted protein degradation: A promise for undruggable proteins

Kusal T. G. Samarasinghe, Craig M. Crews

Summary: Protein homeostasis is crucial for maintaining a balanced, healthy environment within cells, but excessive dysregulated proteins can lead to disease. PROTACs and other Targeted Protein Degradation (TPD) strategies are emerging as potential therapeutic modalities for degrading disease-causing proteins, including previously undruggable targets like transcription factors.

CELL CHEMICAL BIOLOGY (2021)

No Data Available